All In Biotech

Drug Trial Radar · NCT07831122

Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)

An Open-Label Phase Ib, Multicenter Study To Evaluate The Safety And Efficacy Of Belantamab Mafodotin Plus Cevostamab And Pomalidomide In Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 2033

Study completion Mar 2033

Sponsor

Lead sponsor
Canadian Myeloma Research GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline; Hoffmann-La Roche
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.

Conditions

  • Relapsed Refractory Multiple Myeloma (RRMM)

Interventions

  • BelamafDrug

    Administered intravenously

  • CevostamabBiological

    Administered intravenously

  • PomalidomideDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D)Time frame: From the first dose of study drugs until the end of 3 cycles of therapy (up to 9 weeks; each cycle is 21 days) in the last dose-escalation cohort, or until study therapy is discontinued due to disease progression or toxicity, whichever occurs first.
  2. Overall Response Rate (ORR)Time frame: From 3 weeks after the first dose of study therapy (end of Cycle 1; Cycle 1 is 21 days) until the date of documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • The Ottawa Hospital - General Hospital

    Ottawa, Ontario, Canada

  • UHN-Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • Hospital Maisonneuve - Rosemont

    Montreal, Quebec, Canada

  • McGill University Health Centre -MUHC

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.